DGAP-Adhoc

MOLOGEN completes portfolio review: shift from research to product- and market-oriented company - Seite 2

planning of the company. Until final data from the ongoing trial IMPALA is
available, presumably in the second half of 2018, MOLOGEN AG currently
still estimates unaltered financing needs which exceed the existing
liquidity and which have to be covered to complete the IMPALA trial.

The Executive Board will present the strategic program to shareholders at
the annual shareholders' meeting which is now scheduled for 11 August 2016.
In order to meet the financing needs, it is likely that the shareholders'
meeting will be asked to approve a cash capital increase with subscription
rights.

- End of the ad-hoc notification -

DISCLAIMER
This announcement does not constitute an offer to buy shares or other
securities of MOLOGEN AG and does not replace the prospectus. This
announcement does not contain or constitute an offer of, or the
solicitation of an offer to buy or subscribe for, securities to any person
in the United States of America (the "United States"), Australia, Canada or
Japan or in any jurisdiction. The securities referred to in this
announcement will not be and have not been registered under the U.S.
Securities Act of 1933, as amended (the "U.S. Securities Act") and may not
be offered or sold in the United States absent registration or an
applicable exemption from registration requirements under the U.S.
Securities Act. There will be no public offer of the securities in the
United States. Subject to certain exceptions, the securities referred to in
this announcement may not be offered or sold in Australia, Canada or Japan,
or to, or for the account or benefit of, any national, resident or citizen
of Australia, Canada or Japan. The offer and sale of the securities
referred to in this announcement has not been and will not be registered
under the U.S. Securities Act or under the applicable securities laws of
Australia, Canada or Japan. There will be no public offer of the securities
in the United States.

Contact
Claudia Nickolaus
Head of Investor Relations & Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Fax: +49 - 30 - 84 17 88 - 50
[e-mail]

Note about risk for future predictions
Certain information in this report contains forward-looking statements or
the corresponding statements with negation or versions deviating from this
or comparable terminology. These are described as forward-looking
statements. In addition, all of the information given here that refers to
planned or future results of business areas, key financial figures,
developments of the financial situation or other financial figures or
statistical data, is to be understood as such forward-looking statements.
The company points out to investors that they should not rely on these
forward-looking statements as predictions about actual future events. The
company is not obligated and refuses to accept any liability for the
forward-looking statements and has no obligation to update such statements
in order to accurately reflect the current situation.


09.06.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: MOLOGEN AG
Fabeckstraße 30
14195 Berlin
Germany
Phone: 030 / 841788-0
Fax: 030 / 841788-50
E-mail: [e-mail]
Internet: www.mologen.com
ISIN: DE0006637200
WKN: 663720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------